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ABSTRACT: ε-Caprolactam and δ-valerolactam are important com-
modity chemicals used in the manufacture of nylons, with millions of
tons produced annually. Biological production of these highly valued
chemicals has been limited due to a lack of enzymes that cyclize ω-
amino fatty acid precursors to corresponding lactams under ambient
conditions. In this study, we demonstrated production of these
chemicals using ORF26, an acyl-CoA ligase involved in the biosynthesis
of ECO-02301 in Streptomyces aizunensis. This enzyme has a broad
substrate spectrum and can cyclize 4-aminobutyric acid into γ-
butyrolactam, 5-aminovaleric acid into δ-valerolactam and 6-amino-
caproic acid into ε-caprolactam. Recombinant E. coli expressing ORF26
produced valerolactam and caprolactam when 5-aminovaleric acid and
6-aminocaproic acid were added to the culture medium. Upon
coexpressing ORF26 with a metabolic pathway that produced 5-
aminovaleric acid from lysine, we were able to demonstrate production of δ-valerolactam from lysine.
Lactams are important compounds used in the manufactureof commercial polymers. ε-caprolactam (caprolactam) is
used in the production of nylon-6 found in fabrics, coatings,
and other plastic products. δ-Valerolactam (valerolactam) has
been proposed as a monomer for nylon 5 and nylon-6,5
synthesis, addition of which tunes the properties of the
resulting polymers.1−3 Currently, both caprolactam and
valerolactam are synthesized from petrochemical sources. For
example, caprolactam production starts from cyclohexanone,
which is ﬁrst converted to its oxime. Treatment of this oxime
with acid induces the Beckmann rearrangement to give
caprolactam.4 Such production involves energy intensive
processes and harsh acidic reaction conditions and produces
large amount of waste salts. Unlike chemical dehydration,
enzymatic or whole-cell-catalyzed reactions can be performed at
lower temperatures and pressure. Although several ω-amino
fatty acids have been biosynthesized,2,5−7 full biosynthetic
pathways to produce lactams are largely unknown. This is due
to a lack of enzymes capable of performing the last ring-closing
step. To date, only one enzyme, Candida antarctica lipase B
(CALB, commercially available as N435), was reported to
conduct a reversible aminolysis reaction that can be utilized for
valerolactam and caprolactam synthesis.8 However, the
reported enzyme requires anhydrous conditions, high temper-
atures and long reaction times. In addition, the intermolecular
aminolysis reaction results in multiple side products, including
macrocyclic dimer and trimer lactams, which are hard to
eliminate during product puriﬁcation. As such, there is no
suitable enzyme capable of synthesizing industrially important
lactams under microbial fermentation conditions.
Previously, ORF26 from Streptomyces aizunensis, was
hypothesized to be either a 4-aminobutyryl-CoA ligase or a
4-guanidinobutyryl-CoA ligase.9−12 Previous work demonstra-
ted that expression of ORF26 in vivo resulted in the formation
of γ-butyrolactam from 4-aminobutyric acid (4-ABA).13 In this
study, we overexpressed and puriﬁed recombinant ORF26 in
Escherichia coli, enabling us to explore the catalytic properties of
this enzyme. ORF26 has broad substrate speciﬁcity, acting on
linear or branched acid substrates with positively charged or
neutral functional groups on the ω carbon. Yet the enzyme is
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selective against negatively charged groups on the ω carbon.
ORF26’s ability to activate ω-amino fatty acids led to its
application as a general lactam synthase, enabling biosynthesis
of butyrolactam, valerolactam and caprolactam (Figure 1).
Comparative study of ORF26’s reaction products for diﬀerent
ω-amino fatty acid precursors was performed to better
understand this enzyme’s activity as a lactam synthase.
To apply ORF26 for renewable chemical production, ORF26
was overexpressed in E. coli, and both valerolactam and
caprolactam were formed in vivo by feeding their respective
precursors, 5-aminovaleric acid (5-AVA) and 6-aminocaproic
acid (6-ACA). To achieve renewable production of valer-
olactam, we introduced a two-enzyme pathway into E. coli that
converts lysine to 5-AVA. The pathway contains an L-lysine
monooxygenase and a 5-aminovaleramide amidohydrolase
(davB and davA, respectively, from Pseudomonas putida
KT2440).1,14 Introducing the genes encoding the 5-AVA
biosynthetic pathway and a gene encoding a fusion of ORF26
with maltose binding protein, MBP-ORF26, enabled the
production of valerolactam in E. coli from lysine or directly
from glucose.
■ RESULTS
ORF26 Enzymology. Previous eﬀorts to express the gene
encoding ORF26 in vivo resulted in the formation of γ-
butyrolactam from 4-ABA.13 In order to further explore the
catalytic properties of ORF26, we overexpressed and puriﬁed
recombinant ORF26 in E. coli (Table 1, Figure S1) and tested it
against a range of acid substrates (Table 2) using an ATP-PPi
release assay. The ATP-PPi release assay allowed us to measure
ORF26’s ability to activate various acid substrates with ATP.
Following the ATP-PPi release assay, the samples were
analyzed via LC−MS for product formation. Various apparent
kinetic parameters were estimated for a total of 13 diﬀerent
substrates while assessing acyl-CoA or lactam formation (Table
2, Figure S2). The substrates included (1) short hydroxy- or
amino-butyric acids (3-hydroxybutyric, 3-aminobutyric and 2-
aminobutyric acid), (2) medium-chain acids (valeric and 4-
methyl-hexanoic acid), (3) the ω-amino fatty acids (4-ABA, 5-
AVA and 6-ACA), (4) ω-guanidino fatty acids (4-guanidino-
butyric and 6-guanidinohexanoic acid), and (5) dicarboxylic
acids (glutaric, glutamic and adipic acid). In lactam formation,
ORF26 demonstrated broad cyclase activity toward all three ω-
amino fatty acids substrates. 4-ABA, 5-AVA and 6-ACA were
cyclized into butyrolactam, valerolactam and caprolactam,
respectively. As an acyl-CoA ligase, ORF26 demonstrated
ligase activity toward the previously hypothesized 4-guanidino-
butyric acid, the longer 6-guanidinohexanoic acid and medium
chain valeric and 4-methyl-hexanoic acids. ORF26 had optimal
activity at pH 8.0 (Figure S3), and therefore all in vitro
reactions were conducted at pH 8.0. The enzyme precipitated
and became inactive when the pH dropped below 6.0 (Figure
S3).
Since ORF26 was hypothesized to be an acyl-CoA ligase,9−12
we anticipated that the ORF26-catalyzed reactions would
require ATP or ADP hydrolysis to form the acyl-CoA from the
acid and free CoA. As such, we monitored the in vitro reactions
for both nucleotide products, in addition to the desired lactams.
LC−MS analysis of nucleotides (ATP, ADP, AMP) showed
that ORF26 catalyzed a series of reactions (Figure S5). In the
absence of ORF26, ATP remained stable throughout the
reaction (Figure S6A). In the presence of ORF26 and absence
of ω-amino fatty acid substrates, ATP was hydrolyzed to ADP
and Pi and small amounts of AMP and PPi (Figure S6B). When
ω-amino fatty acids were added into the reaction mixture, the
enzyme hydrolyzed ATP to predominantly AMP and PPi at a
signiﬁcantly higher rate with less formation of ADP and Pi.
These results suggest that the observed signal increase in the
ATP-PPi assay in the presence of ω-amino fatty acid substrate
is due to ATP hydrolysis mainly from acid activation and a
small fraction from nonspeciﬁc ATP hydrolysis by ORF26.
For lactam production, ORF26 demonstrated a higher
substrate aﬃnity for 5-AVA (Km = 0.08 mM), followed by 6-
ACA (Km = 0.16 mM) and 4-aminobutyric acid (Km = 4.96
mM), using a constant concentration of ATP and CoA.
Moreover, ORF26 demonstrated higher catalytic activity on 5-
AVA (kcat/Km = 91.91 min
−1 mM−1), followed by 6-ACA (kcat/
Km = 35.85 min
−1 mM−1) and the lowest on 4-aminobutyric
acid (kcat/Km = 1.83 min
−1 mM−1). For acyl-CoA production,
ORF26 demonstrated catalytic activity for both the 6-
guanidinohexanoic acid (kcat/Km = 77.83 min
−1 mM−1) and
4-guanidinobutyric acid (kcat/Km = 18.25 min
−1mM−1) (Table
2, Figure S2, Figure S4). In addition to acting on guanidino-
containing substrates, ORF26 also demonstrated activity
toward valeric acid (kcat/Km = 3.74 min
−1 mM−1) and 4-
Figure 1. Proposed butyrolactam, valerolactam and caprolactam
formation from their respective linear substrates catalyzed by ORF26.
Table 1. E. coli Strains, Plasmids Used
engineered strains plasmids host
JZ-171 pBbE2C-ORF26 JW2637−4
JZ-172 pBbE2C-RFP JW2637−4
JZ-440 pBbA7a-DavB-DavA BL21(DE3) star
JZ-441 pBbA7a-DavB-DavA + pET28a-MBP-ORF26 BL21(DE3) star
plasmid backbone source (restriction site) gene source (direct digestion or PCR)
pET28b-ORF26 pET28b (NdeI, XhoI) pDNA2.0-ORF26 (NdeI, XhoI)
pET28a-MBP-ORF26 pET28a-MBP (NdeI, XhoI) pDNA2.0-ORF26 (NdeI, XhoI)
pBbA7a-DavB-DavA pBbA7a-RFP (BglII, XhoI) DavB, DavA gBlock
pET28b-CaiC pET28b (NdeI, XhoI) CaiC gBlock
ACS Synthetic Biology Research Article
DOI: 10.1021/acssynbio.6b00372
ACS Synth. Biol. 2017, 6, 884−890
885
methyl-hexanoic acid (kcat/Km = 11.68 min
−1 mM−1). No
activity was detected for the remaining substrates.
Although ORF26 was predicted to be an acyl-CoA ligase,
CoA was not required for lactam formation (Figure S6C, E, and
G). The minimal lactam formation system consisted of ORF26,
ω-amino fatty acids, ATP and Mg2+ (Figure S7). Valerolactam
formation was most rapid, followed by caprolactam and
butyrolactam in the absence of CoA. In addition to using
ATP, ORF26 could also utilize ADP to activate ω-amino fatty
acids and catalyze lactam formation. The ADP reaction
occurred at ∼20−50% of the rate compared to the ATP
reaction (Figure S6I−K).
Valerolactam and Caprolactam Production In Vivo. To
demonstrate valerolactam or caprolactam production using
whole-cell catalysts, we exogenously added the respective
precursors, 2 g/L (20 mM) 5-AVA or 2 g/L (17.7 mM) 6-
ACA, to E. coli BL21 (DE3) star expressing pET28-ORF26
(Figure 2A,B). Both valerolactam and caprolactam were
observed in the medium upon ORF26 expression (Figure
2A,B). An empty pET28 vector was utilized as a control. After
72 h, exogenous feeding of 5-AVA and 6-ACA to the pET28-
ORF26 strain produced a total of 152.7 mg/L (1.5 mM) of
valerolactam and 2.02 mg/L (17.9 μM) of caprolactam,
respectively. The empty pET28 vector control displayed
valerolactam production of 48.6 mg/L (0.5 mM) and no
detectable levels of caprolactam. Valerolactam production in
the empty pET28 strain suggests either a spontaneous ring
closure of the linear molecule, or enzyme catalysis from
endogenous host acyl-CoA enzymes. The native E. coli CaiC, a
known crotonobetaine CoA ligase, was previously shown to
accept 4-aminobutyric acid as substrate and catalyze the
formation of butyrolactam,13 and its activity for 5-AVA and
6-ACA was also determined and compared to ORF26 (Figure
2A,B). After 72 h, the E. coli strain expressing pET28-CaiC
produced 188.8 mg/L (1.9 mM) of valerolactam. No detectable
level of caprolactam was observed. These results suggest a
broader substrate promiscuity of ORF26 as a lactam synthase in
the presence of 2 g/L lactam precursors 5-AVA and 6-ACA.
On the basis of these results, and with the aim of further
investigating ORF26 in achieving renewable production of
Table 2. Steady State Parameters of ORF26a,c
aThe kinetic parameters of ORF26 were determined in a 100 mM HEPES, pH 7.5 at 25 °C using the ATP-PPi release assay using 5 μM ORF26, 1
mM CoA and 1 mM ATP. bOther nonproduct forming pathways could occur such as ATP hydrolysis or acyl-OAMP intermediate hydrolysis.
cFurther kinetic analysis can be found in Figure S2.
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valerolactam, we introduced a two-enzyme pathway, which
converts lysine to 5-AVA into E. coli BL21 (DE3) star, resulting
in strain JZ-441 (Table 1).1−3,14 The pathway contains an L-
lysine monooxygenase and a 5-aminovaleramide amidohydro-
lase (davB and davA, respectively, from Pseudomonas putida
KT2440).1,14 Introducing the genes encoding the 5-AVA
biosynthetic pathway and a gene encoding a fusion of ORF26
with maltose binding protein, MBP-ORF26, enabled the
production of valerolactam in E. coli from lysine (Figure 3A).
JZ-440, which contains both davA and davB but lacks MBP-
ORF26, was used as a negative control. Cultures of JZ-441 and
JZ-440 were supplemented with 0, 1, 5, and 10 g/L of lysine.
Samples were collected at 24, 48 and 72-h time points and
analyzed via LC−MS. A linear trend was observed in
valerolactam production with increasing supplemented lysine
(Figure 3B). Cells growing in medium supplemented with 10
g/L of lysine produced a maximum of 705 mg/L of
valerolactam after 72 h. At 0 g/L lysine feeding, JZ-441
produced 146 mg/L of valerolactam after 72 h (Figure 3B). JZ-
440, which lacks MBP-ORF26, produced measurable levels of
valerolactam, producing a maximum of 67 mg/L after 72 h
when supplemented with 10 g/L of lysine. This is most likely
due to the catalysis from endogenous acyl-CoA ligase host
enzymes.13
The three-enzyme JZ-441 strain utilizes lysine, which is
converted to 5-AVA by the DavB-DavA enzymatic pathway and
subsequently converted into valerolactam by MBP-ORF26. In
order to identify the bottleneck of this three-enzyme pathway,
we measured lysine consumption and 5-AVA production in
both JZ-440 and JZ-441 strains when cultured with 0 g/L, 1 g/
L (6.84 mM), 5 g/L (34.2 mM) and 10 g/L (68.4 mM) lysine
(Figure S9). After 24 h, both JZ-440 and JZ-441 consumed
more than half of the endogenously added lysine (Figure
S9A,B). By 72 h, the majority of the supplemented lysine was
converted into 5-AVA (Figure S9C,D), suggesting high stability
and catalytic eﬃciency of both DavB and DavA in E. coli.
Overall, these results suggest cyclization of 5-AVA to
valerolactam by ORF26 is the rate-limiting step in this three-
enzyme pathway.
■ DISCUSSION
Natural product biosynthesis continues to be a rich source of
enzyme candidates with novel biochemical activities. ORF26,
an enzyme in the Streptomyces aizunensis ECO-02301
biosynthetic cluster, was identiﬁed to be a 4-guanidinobutyr-
yl-CoA ligase, which has interesting implications for the ECO-
02301 loading mechanism.12,15,16 ORF26 activated a wide range
of medium chain fatty acid substrates and their functionalized
analogs. Both linear and branched fatty acids were accepted as
substrates. However, the enzyme seems to have little tolerance
of polar groups at C3 position. ORF26 displays substrate
promiscuity toward positively charged substrates, such as the ω-
amino fatty acids or the ω-guanidino fatty acids, despite the fact
that some substrates such as 6-guanidinohexanoic acid have two
more carbons in their backbone than the putative native
substrate. However, enzyme activity on substrates that have a
negatively charged group on the ω-terminal end, such as a
carboxylic acid group, was not observed, even though glutaric
acid and adipic acid have similar steric hindrance as 6-
guanidinohexanoic acid. This suggests that ORF26 has strict
substrate charge speciﬁcity and preferentially favors substrates
with a positively charged group on the ω-terminal end.
Figure 2. In vivo lactam production by ORF26 and CaiC supplemented with 5-aminovaleric acid or 6-aminocaproic acid. (A) Valerolactam
biosynthesis by ORF26 and CaiC using autoinduction ZYM-5052 medium supplemented with 2 g/L of 5-aminovaleric acid. (B) Caprolactam
biosynthesis by ORF26 and CaiC using autoinduction ZYM-5052 medium supplemented with 2 g/L of 6-aminocaproic acid. Empty pET28 vector
was used as a negative control. Not detected is denoted by N.D.
ACS Synthetic Biology Research Article
DOI: 10.1021/acssynbio.6b00372
ACS Synth. Biol. 2017, 6, 884−890
887
The ability of ORF26 to accept various ω-amino fatty acids
was explored for lactam biosynthesis. For lactam formation,
ORF26 does not require CoA as substrate. The activation of ω-
amino fatty acids by ATP facilitates cyclization. This enables
ﬁve-membered, six-membered and even seven-membered ring
formation at mild temperatures, resulting in the production of
important industrial lactams such as valerolactam and
caprolactam via fermentation. Unlike the reversible aminolysis
enzyme CALB that was previously described, ORF26 performs
the reaction under ambient conditions. The lactam product
observed is exclusively cyclized monomer, without dimer or
trimer contaminants. These novel features make ORF26 an
ideal candidate for lactam biosynthesis. However, the enzyme
catalyzed signiﬁcant ATP and ADP hydrolysis during the
reaction. Directed evolution of ORF26 toward less futile ATP
and ADP hydrolysis could potentially improve ORF26 as a
lactam synthase.
By introducing davB and davA into E. coli, we demonstrated
valerolactam biosynthesis from lysine. Valerolactam production
in autoinduction medium was lysine dependent. At concen-
trations of lysine below 1 g/L, valerolactam production
correlated with the lysine concentration from the ZYM-5052
medium. High concentrations of lysine (e.g., 10 g/L) resulted in
∼5 fold increase in valerolactam production compared to
nonsupplemented cultures. Even without lysine feeding, direct
lysine production from endogenous lysine and glucose was
suﬃcient to produce ∼50% of the valerolactam produced when
5 g/L lysine was fed to the culture. Interestingly, in the absence
of ORF26 a small amount of valerolactam was observed (Figure
3B, Figure S9). The observed valerolactam could result from
catalysis by innate E. coli enzymes, most likely CaiC.
Caprolactam was also biosynthesized by feeding its precursor
6-aminocaproic acid. With an already established 6-amino-
caproic acid biosynthetic pathway in E. coli, ORF26 holds
promise to enable full caprolactam biosynthesis in a microbial
host.6,7
■ CONCLUSION
ORF26 is an enzyme in the ECO-02301 biosynthetic cluster
previously identiﬁed to catalyze 4-guanidinobutyryl-CoA
formation and was able to activate a wide range of substrates.
While acting on ω-amino fatty acids, ORF26 can catalyze the
ring closing reaction to produce butyrolactam, valerolactam and
caprolactam. Biosynthesis of polymer precursors such as
caprolactam, valerolactam and butyrolactam were demonstrated
from their respective ω-amino fatty acids. E. coli harboring a
Figure 3. Valerolactam production in recombinant E. coli. (A) Valerolactam biosynthesis pathway. (B) Production of valerolactam via fermentation.
Titer gain by day 1−3 after induction in strains JZ-440 and JZ-441 from 0, 1, 5 and 10 g/L lysine feeding. JZ-440, lacking ORF26 served as a negative
control. Not detected is denoted by N.D.
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pathway to convert lysine to 5-AVA and ORF26 were able to
produce valerolactam from lysine or glucose.
■ MATERIALS AND METHODS
Strains and Plasmids. All the strains and plasmids utilized
in this study are listed in Table 1. The link to the plasmids
sequence information is listed in Supporting Information
(Table S1).
ORF26 Protein Expression and Puriﬁcation. The gene
encoding ORF26 (GenBank: AAX98201.1) was purchased
from DNA 2.0 (Menlo Park, CA). The synthetic gene was
optimized with E. coli codon usage and delivered in pDNA2.0-
ORF26. For expression and puriﬁcation of ORF26, the
pDNA2.0-ORF26 plasmid was digested with NdeI and XhoI
and cloned into pET28b in order to produce ORF26 with an
N-terminal 6xHis tag. The resulting plasmid, pET28b-ORF26,
was transformed into E. coli BL21 Star (DE3) for ORF26
overexpression. pET28-CaiC was cloned using the same NdeI
and XhoI restriction site cloning methodology as pET28-
ORF26.
For the N-terminal 6xHis ORF26 expression, the overnight
culture was inoculated (1:100 v/v) into 1 L of Luria−Bertani
(LB) media containing 50 μg/mL kanamycin. The culture was
grown at 37 °C until the OD600 nm (optical density measured at
a wavelength of 600 nm) reached 0.6 and cooled on ice for 20
min. 0.5 mM IPTG was added to induce pET28-ORF26
overexpression for 16 h at 18 °C. The cells were harvested by
centrifugation (8000g, 10 min, 4 °C), resuspended in 40 mL of
lysis buﬀer (50 mM HEPES, pH 8.0, 0.3 M NaCl, 10% glycerol
(v/v) and 10 mM imidazole), and lysed by sonication on ice.
Cellular debris was removed by centrifugation (20 000g, 60
min, 4 °C). The N-terminal 6xHis ORF26 protein was puriﬁed
by ThermoFisher HisPur cobalt resin, dialyzed against 50 mM
HEPES, pH 8.0, 1 mM DTT and 8% glycerol (v/v). The
dialyzed proteins were concentrated to 18 mg/mL using 10
kDa MWCO Amicon Ultra ﬁlters (Millipore). Concentrated
6xHis ORF26 protein was aliquoted, ﬂash frozen in liquid
nitrogen and stored at −80 °C. Both DNA and protein
concentrations were determined using a Nanodrop 1000
spectrophotometer (Thermo Scientiﬁc). The puriﬁed ORF26
was checked on SDS-PAGE gel for purity (Figure S1).
ATP-PPi Release Assays for ORF26. The substrate range
of ORF26 was determined by ATP-PPi release assays as
previously described.12 Without prior knowledge about the
reaction pathways, the ATP-PPi assay served a semiquantitative
method to compare substrate-induced acceleration of ATP
consumption. For kinetic investigation of ORF26 activity with
diﬀerent substrates, the inorganic pyrophosphate released by
enzymatic reaction was measured continuously using the
EnzChek Pyrophosphate Assay Kit (Invitrogen). A typical
assay contained in a total volume of 150 μL: 5 μM of ORF26,
0−60 mM substrates, 1 mM ATP, 1 mM CoA and 1 mM
MgCl2 in 100 mM HEPES, pH 7.5. 2-amino-6-mercapto-7-
methylpurine ribonucleoside (MESG), purine nucleoside
phosphorylase and inorganic pyrophosphatase were added
according to the protocol. Reactions were initiated by the
addition of ATP and monitored at 360 nm with SpectraMax
M2 (Molecular Devices, Sunnyvale, CA). Initial velocities were
calculated using the standard curve for inorganic pyrophos-
phate. For each substrate, control reactions were carried out
without enzyme or without ATP. The rates of PPi release were
converted to observed rates, and Michaelis−Menten kinetic
parameters were estimated using GraphPad prism software
(GraphPad Prism version 7.00 for Mac OS X, GraphPad
Software, La Jolla California USA, www.graphpad.com) (Figure
S2). The acids assayed are listed in Table 2 (Sigma-Aldrich).
During preparation of substrate stock solution, 6-guanidinohex-
anoic acid displayed low solubility under neutral pH, and HCl
was added to obtain 100 mM stock solution in pH ∼ 2.0.
4-Guanidinobutyryl CoA Product Identiﬁcation. To
conﬁrm ORF26’s native activity as a 4-guanidinobutyryl CoA
ligase, the quenched reaction with 4-guanidinobutyric acid was
analyzed for CoA products as described previously.17 The mass
measurements were carried out in the TOF-Scan monitoring
mode for the detection of [M − H]− ions (4-guanidinobutyrl-
CoA, m/z = 893.1825). Negative controls were carried out
using no enzyme, no ATP, no substrate or no CoA.
Product Analysis of In Vitro ORF26 Lactam Formation.
To compare formation of various lactams by ORF26, a reaction
mixture containing 57 μM of ORF26, 5 mM ω-amino fatty
acids substrates, 1 mM ATP or ADP, 1 mM CoA and 1 mM
MgCl2 in 100 mM HEPES (pH = 8) were incubated at 25 °C.
The reactions were quenched by addition of methanol to a ﬁnal
concentration of 50% (v/v) at multiple time points (0 min, 15
min, 1 h, 2 h, 4 and 19 h). The resulting quenched reactions
were kept at 4 °C and ﬁltered through a 3 kDa MWCO Amicon
Ultra-0.5 mL Centrifugal Filters (Millipore) at 8000g for 30
min. The ﬁltered solutions were analyzed for lactams and
nucleotides using HPLC−MS (see Supporting Information).
Control reactions were carried out without enzyme, without
substrate, without ATP, without CoA or without MgCl2
(supplying additional 0.2 mM EDTA to chelate Mg2+ ions
from puriﬁed protein stock). Caprolactam, valerolactam,
butyrolactam, AMP, ADP and ATP were purchased as
standards (Sigma-Aldrich). The pH dependence of ORF26-
catalyzed butyrolactam formation was determined using an
end-point assay, and the amount of butyrolactam was
determined using the HPLC−MS method described above.
In Vivo Lactam Production. E. coli JW2637−4 contains a
knockout of gabT, which encodes a GABA transaminase.18 This
host was initially used to conﬁrm production of valerolactam
and caprolactam in vivo. E. coli JZ-171 (ORF26) and JZ-172
(RFP negative control) were inoculated overnight in LB
medium, which was prepared from dehydrated powder
according to the manufacturer’s instructions (BD Biosciences,
San Jose, CA). The overnight culture was diluted to OD600 nm ∼
0.01 in LB medium and induced with 50 ng/mL anhydrote-
tracycline when OD600 nm reached ∼0.6. 5-AVA and 6-ACA
were added exogenously into the medium to reach a ﬁnal
concentration of 1 mM. To analyze 24 h lactam production,
600 μL of culture were taken for each sample and cooled in 4°
room. The samples were spun at 13 000 rpm for 10 min, and
500 μL of supernatant was taken and ﬁlter spin at 13 000 rpm
for 10 min (0.5 mL 3000 MW cutoﬀ ﬁlter, EMD Millipore).
100 μL ﬁltered supernatant was taken and mixed 1:1 volume
with MeOH.
For the in vivo lactam production comparison between
ORF26 and CaiC, E. coli BL21 (DE3) star cells were used as a
host containing either pET28-ORF26 or pET28-CaiC. Cultures
were grown in 10 mL of autoinduction ZYM-5052 medium
according to the published protocol.19 5-AVA and 6-ACA were
added exogenously into the medium to reach a ﬁnal
concentration of 2 g/L. Samples were cultured at 200 rpm
and 25 °C. Samples taken at 24, 48 and 72 h were prepared and
analyzed as previously described.
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genes were ordered as gBlocks (Integrated DNA Technologies,
Coralville, IA) and cloned into the BglII and XhoI sites on
pBbA7, a biobrick vector, to generate plasmid pBbA7a-DavB-
DavA.20 To circumvent ORF26’s limited solubility during
incubation, MBP-ORF26 was utilized.13 For high-density shake
ﬂask cultures, Studier’s autoinduction ZYM-5052 medium was
prepared according to the published protocol.19 Lysine at
various concentrations (0, 1, 5 and 10 g/L) was included in the
ZYM-5052 medium. Kanamycin (20 μg/mL) and ampicillin
(100 μg/mL) were added where desired to provide selective
pressure for plasmid maintenance.
E. coli strains (JZ-441) harboring plasmids containing davA,
davB and MBP-ORF26 were inoculated into 10 mL of LB
overnight. On day 2, the overnight culture was inoculated 1:100
(v/v) into 25 mL Studier’s autoinduction ZYM-5052 medium
with various concentrations of lysine (0 g/L to 10 g/L) and
appropriate antibiotics.19 The culture was incubated at 37 °C.
When the OD600 nm reached around 0.6, the culture was cooled
to 25 °C. The culture was then placed at 25 °C incubator and
the valerolactam titer was analyzed at 24, 48 and 72 h. JZ-440,
which contains only davA and davB, served as a negative
control.
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